UnitedHealth Group Inc., the nation’s largest health insurer by membership, delivered a narrow earnings beat for the fourth quarter of 2025 but stunned investors with revenue guidance signaling the first annual sales decline in over a decade. Adjusted earnings per share came in at $2.11, edging past Wall Street’s $2.10 expectation, while revenue totaled $113.2 billion, missing the $113.82 billion forecast, according to details from the company’s earnings release reported by CNBC.
The results cap a turbulent 2025 marked by soaring medical costs, a cyberattack on its Optum unit, federal probes into Medicare Advantage billing, and the murder of a top executive. Shares plunged more than 12% in premarket trading on January 27, 2026, extending a yearly drop exceeding 30%, as traders digested the outlook for purposeful contraction. Full-year 2025 adjusted operating earnings reached $21.7 billion, but a $1.6 billion after-tax charge—tied to cyberattack remediation, divestitures, and restructuring—hammered reported net income to just $10 million for the quarter.
Medical care ratio for the insurance segment hit 92.4% in Q4, above the 92.1% estimate, reflecting persistent pressures from pent-up procedures like joint replacements among Medicare Advantage enrollees. Optum Health revenues fell 3% to $102 billion for the year, swinging to an adjusted operating loss amid reimbursement squeezes.
Guidance Signals Shrink-to-Grow Strategy
For 2026, UnitedHealth projected revenue exceeding $439 billion, a roughly 2% drop from 2025 levels and well below analysts’ $454.6 billion consensus. CFO Wayne DeVeydt pinned the downturn on Q4 divestitures—including South American and European operations—a planned U.S. membership shed of over 3 million, primarily in unprofitable Medicare Advantage and ACA plans, and a $6 billion drag from the final year of Medicare’s V28 coding transition ($2 billion to UnitedHealthcare, the rest to Optum), as detailed in CNBC.
Despite the top-line pullback, adjusted EPS guidance topped $17.75, surpassing the $17.69 estimate, with medical benefit ratio improving to 88.8% (±50 basis points) from 89.1% in 2025. Operating cash flow was pegged above $18 billion, operating margin around 5.5%, and share repurchases at $2.5 billion. “We confronted challenges directly and finished 2025 as a much stronger company, giving us the momentum to better serve those who count on us,” the company stated in its release, per X posts from analysts like @StockSavvyShay.
UnitedHealthcare revenues grew 16% to $344.9 billion in 2025, serving 49.8 million consumers, with Medicare Advantage enrollment up 755,000 including complex cases. Optum revenues rose 7% to $270.6 billion, aiding 123 million consumers.
Divestitures and Portfolio Restructuring
DeVeydt outlined a multi-year reset, including closing 550 Optum sites, exiting loss-making contracts, and refocusing on domestic value-based care. International sales like U.K. and South America are in motion, with more to follow by mid-2026, aiming to slash debt, resume aggressive buybacks in H2 2026, and bolster the balance sheet. This follows a three-year turnaround blueprint unveiled in November 2025, emphasizing pricing discipline for 10% medical cost trends and Optum integration.
Prior quarters exposed vulnerabilities: Q1 and Q2 2025 saw earnings misses—the first in over 60 quarters—prompting CEO Stephen Hemsley’s return in May and guidance suspensions, as chronicled by Reuters. Hemsley, who bought $25 million in stock post-return, faces Senate scrutiny over MA upcoding tactics revealed in a Wall Street Journal probe.
Analysts like Bernstein’s Lance Wilkes, who named UNH his top 2026 healthcare pick with a $444 target, see margin lift from business exits, per TipRanks. Morgan Stanley’s Erin Wright anticipates a “clean print” with potential EPS guide lift above $17.55, citing disciplined MA resets.
Medical Cost Pressures Persist
Medicare Advantage costs remain elevated post-pandemic, with CMS’s flat 2026 rates—announced days before earnings—adding fuel to the selloff. UnitedHealthcare expects 88.8% MBR, but sector-wide reimbursement cuts and V28 transitions weigh heavy. Full-year 2025 MCR hit 88.9%, up from 85.5% in 2024 due to funding reductions and Inflation Reduction Act changes.
Optum Health, hit by cyber fallout and MA pressures, posted a $278 million operating loss on $102 billion revenue. Optum Insight ramps AI hires for analytics, targeting recurring revenue acceleration. Optum Rx grew via client wins. X reactions highlighted margin woes: operating margin at 0.3% vs. 2.9% expected, per @wallstengine.
Berkshire Hathaway’s $1.57 billion stake and Hemsley’s conviction signal long-term bets, but near-term visibility hinges on execution amid policy risks like ACA rebates and DOJ probes, as noted in Nasdaq.
Investor Reactions and Sector Ripples
Premarket drop to $307.98 from $351.64 reflected disappointment, with options implying 5.54% moves but reality exceeding that. X users like @LeverageETFs noted $1.6 billion charges; @DeepIceValue praised pre-earnings optimism now tested. Seeking Alpha flagged guidance as focal point post-Hemsley’s return.
Wall Street holds Strong Buy consensus, average target $399 implying 17-25% upside, per TipRanks and Barchart. Evercore’s Elizabeth Anderson sees 2026 transition year with $400 target. Yet, 2025’s 41% EPS plunge to $16.30 underscores reset pains.
As bellwether, UNH sets tone for Humana, Elevance; peers dipped on news. Hemsley’s track record—13-16% long-term EPS growth—fuels hope for 2027 acceleration, but investors demand proof on cost alignment and membership stabilization.
WebProNews is an iEntry Publication